Eris Lifesciences Ltd (ERIS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Eris Lifesciences Ltd (ERIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8227
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eris Lifesciences Ltd (Eris Lifesciences) is a health care products and service provider. The company offers glimepride, telmisertan, methylcobalamin and combinations, vitamin d, rabeprazole, olmesartan, mecobalamin colecalciferol, teneligliptin, rosa canina extract, cilnidipine, atorvastatin, conventional iron, gliclazide, rosuvastatin and sultamicillin products. It provides medicines to cardiovascular, anti-diabetes, vitamins and nutrients, gastroenterology, gynaecology, pediatrics, respiratory, neurology, psychiatry, and pain and analgesics. Eris Lifesciences provides anti diabities medicines such as glimepiride and combinations, teneligliptin and combinations, gliclazide and combinations and voglibose and combinations. The company offers products in the form of tablets, capsules and sachets. It markets through chemist outlets. The company has manufacturing facility located at Assam. Eris Lifesciences is headquartered in Ahmedabad, Gujarat, India.

Eris Lifesciences Ltd (ERIS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Eris Lifesciences Acquires Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
Licensing Agreements 15
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 15
Equity Offering 16
Eris Lifesciences Raises USD270 Million in IPO 16
Acquisition 18
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd – Key Competitors 25
Eris Lifesciences Ltd – Key Employees 26
Eris Lifesciences Ltd – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Other Significant Developments 28
Aug 17, 2017: Eris Lifesciences Announces the Dhifting of the Registered Office of the Company 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eris Lifesciences Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Eris Lifesciences Acquires Branded Generics Business from Strides Shasun for USD76.7 Million 12
Eris Lifesciences Acquires 40 Trademarks from Amay Pharma for USD5 Million 14
Aprica Healthcare Enters into Licensing Agreement with Eris Lifesciences 15
Eris Lifesciences Raises USD270 Million in IPO 16
Eris Lifesciences Acquires UTH Healthcare for USD2 Million 18
Eris Lifesciences Acquires Additional 14% Stake in Kinedex Healthcare for USD2 Million 19
Eris Lifesciences Acquires 61.48% Stake in Kinedex Healthcare for USD9.2 Million 20
Eris Lifesciences Acquires Aprica Healthcare 21
ChrysCapital May Sell its Stake in Eris Lifesciences 22
Nrim May Acquire Additional Stake in Kinedex Healthcare 23
Nrim Invests in Kinedex Healthcare 24
Eris Lifesciences Ltd, Key Competitors 25
Eris Lifesciences Ltd, Key Employees 26
Eris Lifesciences Ltd, Subsidiaries 27

List of Figures
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eris Lifesciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eris Lifesciences Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Eris Lifesciences Ltd (ERIS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Guizhou Space Appliance Co., Ltd.:企業の戦略・SWOT・財務情報
    Guizhou Space Appliance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Guizhou Space Appliance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Natcore Technology Inc (NXT):企業の財務・戦略的SWOT分析
    Summary Natcore Technology Inc (Natcore) is a solar research and development company that provides products for semiconductor and fiber optic applications. The company’s products include solar cell structures and black silicon cells. It uses liquid phase deposition technology for controlling deposit …
  • Mapletree Investments Pte Ltd:企業の戦略的SWOT分析
    Mapletree Investments Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • PositiveID Corp (PSID):企業の財務・戦略的SWOT分析
    Summary PositiveID Corp (PositiveID), formerly VeriChip Corp is a life sciences tools and diagnostics company that develops biological detection and molecular diagnostic systems. The company develops microfluidic systems for automated preparation and performance of biological assays. Its products in …
  • Boston Children’s Hospital-製薬・医療分野:企業M&A・提携分析
    Summary Boston Children's Hospital (Boston Children’s) is the pediatric medical center that provides a comprehensive range of health care services for children from birth through 21 years of age. Boston Children’s is the primary pediatric teaching affiliate of Harvard Medical School. The organizatio …
  • Johnson Controls International Plc (JCI):電力:M&Aディール及び事業提携情報
    Summary Johnson Controls International Plc (Johnson Controls) is a diversified technology and multi industrial company. It creates intelligent buildings, integrated infrastructure, efficient energy solutions, and next generation transportation systems. The company provides HVAC equipment, HVAC contr …
  • ResMed Inc. (RMD):医療機器:M&Aディール及び事業提携情報
    Summary ResMed Inc. (ResMed) develops, manufactures and distributes medical equipment for the diagnosis, treatment and management respiratory disorders such as sleep-disordered breathing (SDB), sleep apnea and chronic obstructive pulmonary disease (COPD). Its major products include air flow generato …
  • Red Hill Iron Limited:企業の戦略・SWOT・財務情報
    Red Hill Iron Limited - Strategy, SWOT and Corporate Finance Report Summary Red Hill Iron Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Takara Bio Inc (4974):企業の財務・戦略的SWOT分析
    Summary Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It of …
  • Indian Oil Corp Ltd (IOC):石油・ガス:M&Aディール及び事業提携情報
    Summary Indian Oil Corp Ltd (IOCL) is an integrated oil and gas company that carries out exploration and production of oil and natural gas, refining of crude oil, pipeline transportation and marketing of natural gas and petroleum products. The company also produces and markets petrochemicals and has …
  • Volta River Authority-エネルギー分野:企業M&A・提携分析
    Summary Volta River Authority (VRA) is a state-owned energy utility that generates, transmits, and distributes electricity. The authority produces power from solar, hydro, light crude oil, distillate fuel oil, and heavy fuel oil sources. It procures energy from Takoradi International Company Ltd; an …
  • Avacta Group Plc (AVCT):製品パイプライン分析
    Summary Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products which include optim and sensipod. It also develops UCB celltech, which is an analytical instrument. Avacta’s sensipod is …
  • Novolex Holdings, Inc.:企業の戦略的SWOT分析
    Novolex Holdings, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Banco Bilbao Vizcaya Argentaria SA:戦略・SWOT・企業財務分析
    Banco Bilbao Vizcaya Argentaria SA - Strategy, SWOT and Corporate Finance Report Summary Banco Bilbao Vizcaya Argentaria SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Kalle GmbH:企業の戦略的SWOT分析
    Kalle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Netsmart Technologies Inc:企業の戦略的SWOT分析
    Netsmart Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Finnish Funding Agency for Innovation-製薬・医療分野:企業M&A・提携分析
    Summary Finnish Funding Agency for Innovation (Tekes) is a financing organization that offers research and technological development programs. The organization offers financial services for research, development and novelty. It provides finance for research and development of new technologies, busin …
  • Navitas Ltd:企業の戦略的SWOT分析
    Navitas Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Hanwha Solutions Corp (009830):企業の財務・戦略的SWOT分析
    Summary Hanwha Solutions Corp (Hanwha Solutions), a subsidiary of Hanwha Corp, is a provider of chemicals, solar energy solutions and advanced industrial materials. The company is engaged in the production of inorganic chemical, plastic and polymer products which include chlorine and caustic soda, p …
  • Akzo Nobel NV (AKZA):企業の財務・戦略的SWOT分析
    Akzo Nobel NV (AKZA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆